Jupiter, Florida, Dec. 23, 2025 (GLOBE NEWSWIRE) -- Jupiter Neurosciences, Inc. (NASDAQ: JUNS) (“Jupiter” or the “Company”), a clinical-stage pharmaceutical company developing JOTROL™, a patented resveratrol-based platform, is pleased to invite investors to a webinar on January 6, 2026, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Jupiter Neuroscience Chairman and CEO Chister Rosén who will provide investors with an overview of Jupiter Neurosciences’ scientific platform, c ...

Core Insights - Jupiter Neurosciences, Inc. is a clinical-stage pharmaceutical company focused on developing JOTROL™, a resveratrol-based therapeutic platform aimed at neuroinflammation and mitochondrial dysfunction [1][4] - The company will present at the Noble Capital Markets' 21st Annual Emerging Growth Equity Conference on December 2-3, 2025, providing opportunities for one-on-one meetings with investors [1][2] Company Overview - Jupiter Neurosciences is pursuing a dual-path strategy to address neuroinflammation and promote healthy aging, targeting CNS disorders and rare diseases while also entering the consumer longevity market with its Nugevia product line [4] - The therapeutic pipeline includes a Phase IIa trial for Parkinson's disease and indications such as Alzheimer's Disease and Friedreich's Ataxia [4] Product Details - JOTROL™ has demonstrated over nine times higher bioavailability compared to earlier resveratrol products, addressing the issue of poor bioavailability that has hindered regulatory approval for resveratrol [6] - The Nugevia product line leverages the same clinically validated delivery technology as JOTROL™, offering support for cognitive health, skin vitality, and cellular energy [7]

As filed with the Securities and Exchange Commission on November 26, 2025 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 JUPITER NEUROSCIENCES, INC. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) Delaware 2834 47-4828381 (Primary Standard Industrial Classification Code Number) (I.R.S. Employer Identification Number) Jupiter Neu ...

Core Viewpoint - Jupiter Neurosciences, Inc. has announced the addition of Chris Webber as the second brand ambassador for its new longevity supplement line, Nugevia™, which is based on clinical science and innovative performance-driven technology [1][3]. Company Overview - Jupiter Neurosciences is a clinical-stage pharmaceutical company focused on addressing neuroinflammation and promoting healthy aging through a dual-path strategy that includes advancing therapeutics for CNS disorders and entering the consumer longevity market with Nugevia™ [7]. - The company’s proprietary JOTROL™ platform enhances the bioavailability of resveratrol, which is the foundation for both its therapeutic pipeline and the Nugevia™ product line [10]. Product Details - Nugevia™ features three initial formulations—GLO, MND, and PWR—designed to support cellular resilience through synergistic ingredients optimized for absorption via the JOTROL™ system [4]. - The Nugevia™ brand aims to tap into the rapidly growing longevity market, projected to reach $8 trillion by 2030, creating a revenue stream to support ongoing clinical development and enhance long-term shareholder value [5][6]. Scientific Validation - JOTROL™ has demonstrated over nine times higher bioavailability compared to traditional resveratrol products, as evidenced by a Phase I study published in reputable journals [9]. - The technology aims to provide pharmaceutical-grade bioavailability in the wellness space, targeting cognitive health, skin vitality, and cellular energy [10].

Core Insights - Jupiter Neurosciences, Inc. is launching Nugevia™ GLO, a supplement targeting the "beauty-from-within" market, focusing on skin health through clinically validated cellular science [1][2] - The product utilizes JOTROL™, a proprietary resveratrol delivery technology, and NovaSOL® Astaxanthin, enhancing skin vitality at the cellular level [2][3] - GLO is positioned as a premium supplement, appealing to a demographic of women over 35 seeking scientifically grounded skin and aging solutions [4] Product Details - Nugevia GLO is designed to support skin health by promoting cellular defense, collagen integrity, and hydration [1][4] - The supplement regimen consists of two capsules per day for optimal absorption and compliance [5] - Key benefits include enhanced collagen synthesis, improved hydration, reduced pigmentation, and protection against oxidative stress [7] Market Strategy - The launch of GLO represents a strategic shift for Jupiter into the consumer wellness sector, aiming to create a high-margin revenue stream [4] - The company anticipates significant top-line growth from the Nugevia product line, which will support clinical development and enhance long-term shareholder value [5] - Jupiter is targeting the $8 trillion longevity market, leveraging its proprietary science to reach a broader audience [2] Scientific Validation - JOTROL™ has shown a nine-fold increase in resveratrol bioavailability in Phase I trials, addressing previous issues with resveratrol's effectiveness [3][9] - The combination of JOTROL™ and Astaxanthin is expected to create a leading solution for skin health and systemic rejuvenation [3][10] - Jupiter's therapeutic pipeline includes ongoing clinical programs for CNS disorders, with JOTROL™ serving as a foundation for both therapeutic and consumer products [6][10]